The Global Cardiomyopathy Medication Market is anticipated to reach USD 620 Million by 2025 at a CAGR of ~4.60% during the forecast period. Cardiomyopathy is a disease that causes the thickening and enlargement of the heart muscles and abnormal blood flow. Patients suffering from cardiomyopathy showcase symptoms such as dizziness, coughing, fatigue, and swelling of the legs, ankles, and feet. Certain factors that propel the growth of the global cardiomyopathy medication market are the high patient pool of heart disease, focus on manufacturing medication for cardiomyopathy treatment, and rising healthcare expenditure.